• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

丝状病毒中和抗体:作用机制与治疗应用

Filovirus Neutralising Antibodies: Mechanisms of Action and Therapeutic Application.

作者信息

Hargreaves Alexander, Brady Caolann, Mellors Jack, Tipton Tom, Carroll Miles W, Longet Stephanie

机构信息

Nuffield Department of Medicine, Wellcome Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK.

Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7XH, UK.

出版信息

Pathogens. 2021 Sep 16;10(9):1201. doi: 10.3390/pathogens10091201.

DOI:10.3390/pathogens10091201
PMID:34578233
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8468515/
Abstract

Filoviruses, especially Ebola virus, cause sporadic outbreaks of viral haemorrhagic fever with very high case fatality rates in Africa. The 2013-2016 Ebola epidemic in West Africa provided large survivor cohorts spurring a large number of human studies which showed that specific neutralising antibodies played a key role in protection following a natural Ebola virus infection, as part of the overall humoral response and in conjunction with the cellular adaptive response. This review will discuss the studies in survivors and animal models which described protective neutralising antibody response. Their mechanisms of action will be detailed. Furthermore, the importance of neutralising antibodies in antibody-based therapeutics and in vaccine-induced responses will be explained, as well as the strategies to avoid immune escape from neutralising antibodies. Understanding the neutralising antibody response in the context of filoviruses is crucial to furthering our understanding of virus structure and function, in addition to improving current vaccines & antibody-based therapeutics.

摘要

丝状病毒,尤其是埃博拉病毒,在非洲引发散发性病毒性出血热疫情,病死率极高。2013 - 2016年西非埃博拉疫情产生了大量幸存者群体,促使开展了大量人体研究,这些研究表明,作为整体体液反应的一部分,并与细胞适应性反应协同作用,特定的中和抗体在自然感染埃博拉病毒后的保护过程中发挥了关键作用。本综述将讨论在幸存者和动物模型中描述保护性中和抗体反应的研究。将详细阐述其作用机制。此外,还将解释中和抗体在基于抗体的治疗方法以及疫苗诱导反应中的重要性,以及避免病毒从中和抗体中产生免疫逃逸的策略。除了改进当前的疫苗和基于抗体的治疗方法外,了解丝状病毒背景下的中和抗体反应对于深化我们对病毒结构和功能的理解至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddef/8468515/ce6be08139a7/pathogens-10-01201-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddef/8468515/457ea2392b09/pathogens-10-01201-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddef/8468515/ce6be08139a7/pathogens-10-01201-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddef/8468515/457ea2392b09/pathogens-10-01201-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddef/8468515/ce6be08139a7/pathogens-10-01201-g002.jpg

相似文献

1
Filovirus Neutralising Antibodies: Mechanisms of Action and Therapeutic Application.丝状病毒中和抗体:作用机制与治疗应用
Pathogens. 2021 Sep 16;10(9):1201. doi: 10.3390/pathogens10091201.
2
Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.泛埃博拉病毒和泛丝状病毒小鼠单克隆抗体:对埃博拉病毒和苏丹病毒的保护作用
J Virol. 2015 Oct 14;90(1):266-78. doi: 10.1128/JVI.02171-15. Print 2016 Jan 1.
3
Antibody responses to filovirus infections in humans: protective or not?人体对丝状病毒感染的抗体反应:是否具有保护作用?
Lancet Infect Dis. 2021 Nov;21(11):e348-e355. doi: 10.1016/S1473-3099(21)00006-2. Epub 2021 Jun 24.
4
Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.靶向丝状病毒糖蛋白内新型保守表位的猕猴单克隆抗体。
J Virol. 2015 Oct 14;90(1):279-91. doi: 10.1128/JVI.02172-15. Print 2016 Jan 1.
5
Ferrets Infected with Bundibugyo Virus or Ebola Virus Recapitulate Important Aspects of Human Filovirus Disease.感染本迪布焦病毒或埃博拉病毒的雪貂概括了人类丝状病毒病的重要方面。
J Virol. 2016 Sep 29;90(20):9209-23. doi: 10.1128/JVI.01033-16. Print 2016 Oct 15.
6
Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins.针对多种丝状病毒糖蛋白的双特异性和三特异性抗体的设计与评估。
J Biol Chem. 2018 Apr 20;293(16):6201-6211. doi: 10.1074/jbc.RA117.001627. Epub 2018 Mar 2.
7
Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.单价三价囊泡疫苗可保护猕猴免受致命埃博拉病毒和马尔堡病毒的挑战。
J Virol. 2018 Jan 17;92(3). doi: 10.1128/JVI.01190-17. Print 2018 Feb 1.
8
Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.三价副流感病毒载体埃博拉病毒疫苗诱导的抗体介导的保护机制。
J Virol. 2019 Feb 5;93(4). doi: 10.1128/JVI.01845-18. Print 2019 Feb 15.
9
AAV Vectored Immunoprophylaxis for Filovirus Infections.用于丝状病毒感染的腺相关病毒载体免疫预防
Trop Med Infect Dis. 2020 Nov 9;5(4):169. doi: 10.3390/tropicalmed5040169.
10
A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques.双价、球形病毒样颗粒疫苗增强恒河猴对致病性埃博拉病毒免疫反应的广度。
J Virol. 2020 Apr 16;94(9). doi: 10.1128/JVI.01884-19.

引用本文的文献

1
Thirteen-Year Sequelae of Marburg Virus Disease Survival: Persistent Cardiometabolic, Immunometabolic, and Haematological Alterations in the Absence of Psychological Morbidity.马尔堡病毒病幸存者的13年后遗症:无心理疾病情况下持续存在的心脏代谢、免疫代谢和血液学改变
Pathogens. 2025 Jul 9;14(7):678. doi: 10.3390/pathogens14070678.
2
Rational design of next-generation filovirus vaccines with glycoprotein stabilization, nanoparticle display, and glycan modification.通过糖蛋白稳定化、纳米颗粒展示和聚糖修饰对下一代丝状病毒疫苗进行合理设计。
bioRxiv. 2025 Mar 2:2025.03.02.641072. doi: 10.1101/2025.03.02.641072.
3
Antibodies targeting the glycan cap of Ebola virus glycoprotein are potent inducers of the complement system.

本文引用的文献

1
Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy.在小鼠中进行的 SARS-CoV-2 感染的活体成像研究表明,中和抗体需要 Fc 功能才能发挥最佳疗效。
Immunity. 2021 Sep 14;54(9):2143-2158.e15. doi: 10.1016/j.immuni.2021.08.015. Epub 2021 Aug 18.
2
Adenovirus vector vaccination reprograms pulmonary fibroblastic niches to support protective inflating memory CD8 T cells.腺病毒载体疫苗接种重塑肺部成纤维细胞小生境以支持保护性充气记忆 CD8 T 细胞。
Nat Immunol. 2021 Aug;22(8):1042-1051. doi: 10.1038/s41590-021-00969-3. Epub 2021 Jul 15.
3
Neutralizing monoclonal antibodies for treatment of COVID-19.
针对埃博拉病毒糖蛋白糖帽的抗体是补体系统的有效诱导剂。
Commun Biol. 2024 Jul 17;7(1):871. doi: 10.1038/s42003-024-06556-0.
4
Novel antiviral approaches for Marburg: a promising therapeutics in the pipeline.针对马尔堡病毒的新型抗病毒方法:正在研发中的一种有前景的疗法。
Front Microbiol. 2024 Apr 25;15:1387628. doi: 10.3389/fmicb.2024.1387628. eCollection 2024.
5
Emerging roles of the Protein Phosphatase 1 (PP1) in the context of viral infections.蛋白磷酸酶 1(PP1)在病毒感染背景下的新兴作用。
Cell Commun Signal. 2024 Jan 24;22(1):65. doi: 10.1186/s12964-023-01468-8.
6
Species-specific immunogenicity and protective efficacy of a vesicular stomatitis virus-based Sudan virus vaccine: a challenge study in macaques.基于水疱性口炎病毒的苏丹病毒疫苗的种属特异性免疫原性和保护效力:猕猴挑战研究。
Lancet Microbe. 2023 Mar;4(3):e171-e178. doi: 10.1016/S2666-5247(23)00001-0. Epub 2023 Feb 2.
7
What Do Antibody Studies Tell Us about Viral Infections?抗体研究能告诉我们哪些关于病毒感染的信息?
Pathogens. 2022 May 10;11(5):560. doi: 10.3390/pathogens11050560.
8
Designing a novel multi‑epitope vaccine against Ebola virus using reverse vaccinology approach.利用反向疫苗学方法设计一种针对埃博拉病毒的新型多表位疫苗。
Sci Rep. 2022 May 11;12(1):7757. doi: 10.1038/s41598-022-11851-z.
9
Vaccine-Associated Enhanced Disease and Pathogenic Human Coronaviruses.疫苗相关增强疾病与致病性人类冠状病毒。
Front Immunol. 2022 Apr 4;13:882972. doi: 10.3389/fimmu.2022.882972. eCollection 2022.
10
Pathogenicity and virulence of Marburg virus.马尔堡病毒的致病性和毒力。
Virulence. 2022 Dec;13(1):609-633. doi: 10.1080/21505594.2022.2054760.
用于治疗 COVID-19 的中和单克隆抗体。
Nat Rev Immunol. 2021 Jun;21(6):382-393. doi: 10.1038/s41577-021-00542-x. Epub 2021 Apr 19.
4
Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies.糖萼帽导向的人源抗体对广泛埃博拉病毒中和的共同解决方案的收敛性。
Cell Rep. 2021 Apr 13;35(2):108984. doi: 10.1016/j.celrep.2021.108984.
5
Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.COVID-19 用 Ad26.COV2.S 疫苗的免疫原性。
JAMA. 2021 Apr 20;325(15):1535-1544. doi: 10.1001/jama.2021.3645.
6
Ebolavirus: Comparison of Survivor Immunology and Animal Models in the Search for a Correlate of Protection.埃博拉病毒:幸存者免疫学与动物模型比较,探索保护相关因素。
Front Immunol. 2021 Feb 19;11:599568. doi: 10.3389/fimmu.2020.599568. eCollection 2020.
7
Characterisation of the T-cell response to Ebola virus glycoprotein amongst survivors of the 2013-16 West Africa epidemic.描述 2013-2016 年西非埃博拉疫情幸存者对埃博拉病毒糖蛋白的 T 细胞反应。
Nat Commun. 2021 Feb 19;12(1):1153. doi: 10.1038/s41467-021-21411-0.
8
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.在欧洲(EBOVAC2)进行的一项成人两剂次异源 Ad26.ZEBOV 和 MVA-BN-Filo 埃博拉疫苗方案的安全性和免疫原性:一项随机、观察者盲、参与者盲、安慰剂对照、2 期临床试验。
Lancet Infect Dis. 2021 Apr;21(4):493-506. doi: 10.1016/S1473-3099(20)30476-X. Epub 2020 Nov 17.
9
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.通过 SARS-CoV-2 刺突蛋白变体逃避中和抗体。
Elife. 2020 Oct 28;9:e61312. doi: 10.7554/eLife.61312.
10
Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort study.埃博拉病毒病幸存者和接触者的纵向抗体和 T 细胞反应:一项观察性队列研究。
Lancet Infect Dis. 2021 Apr;21(4):507-516. doi: 10.1016/S1473-3099(20)30736-2. Epub 2020 Oct 13.